Background Exhaled respirable aerosols (<5 μm diameter) present a high risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission. Many guidelines recommend using aerosol precautions during “aerosol generating procedures” (AGPs) and droplet (>5 μm) precautions at other times. However, there is emerging evidence that respiratory activities such as cough and not AGPs are the important source of aerosols. Methods We used a novel chamber with an optical particle counter sampling at 100 L/min to count and size-fractionate all exhaled particles (0.5-25 μm). We compared emissions from ten healthy subjects during respiratory “activities” (quiet breathing, talking, shouting, forced expiratory maneuvers, exercise and coughing) with respiratory “therapies” designated as AGPs: high flow nasal oxygen (HFNO) and single or dual circuit non-invasive positive pressure ventilation, NIPPV-S and NIPPV-D, respectively. Activities were repeated wearing facemasks. Results Compared to quiet breathing, respiratory activities increased particle counts between 34.6-fold (95% confidence interval [CI], 15.2 to 79.1) during talking, to 370.8-fold (95% CI, 162.3 to 847.1) during coughing (p<0.001). During quiet breathing, HFNO at 60 L/min increased counts 2.3-fold (95% CI, 1.2 to 4.4) (p=0.03) and NIPPV-S and NIPPV-D at 25/10 cm H2O increased counts by 2.6-fold (95% CI, 1.7 to 4.1) and 7.8-fold (95% CI, 4.4 to 13.6) respectively (p<0.001). During activities, respiratory therapies and facemasks reduced emissions compared to activities alone. Conclusion Talking, exertional breathing and coughing generate substantially more aerosols than the respiratory therapies HFNO and NIPPV which can reduce total emissions. The risk of aerosol exposure is underappreciated and warrants widespread targeted interventions.
Ethnic disparities in COVID-19 hospitalizations and mortality have been reported but there is scant understanding of how these inequalities are embodied. The UK Biobank prospective cohort study comprises around half a million people who were aged 40-69 years at study induction between 2006 and 2010 when information on ethnic background and potential explanatory factors was captured. Study members were linked to a national mortality registry. In an analytical sample of 448,664 individuals (248,820 women), 354 deaths were ascribed to COVID-19 between 5th March and the end of follow-up on 17th September 2020. In age- and sex-adjusted analyses, relative to White participants, Black study members experienced around seven times the risk of COVID-19 mortality (odds ratio; 95% confidence interval: 7.25; 4.65, 11.33), while there was a doubling in the Asian group (1.98; 1.02, 3.84). Controlling for baseline comorbidities, socioeconomic circumstances, and lifestyle factors explained 53% of the differential in risk for Asian people (1.37; 0.68, 2.77) and 27% in Black study members (4.28; 2.67, 6.86). The residual risk in ethnic minority groups for COVID-19 deaths may be ascribed to unknown genetic factors or unmeasured phenotypes, most obviously racial discrimination.
Background: The unprecedented rapid development of vaccines against the SARS-CoV-2 virus creates in itself a new challenge for governments and health authorities: the effective vaccination of large numbers of people in a short time and, possibly, with shortage of vaccine doses. To whom vaccinate first and in what sequence, if any at all, to avoid the most fatalities remains an open question. Methods: A compartmental model considering age-related groups was developed to evaluate and compare vaccine distribution strategies in terms of the total avoidable fatalities. Population groups are established based on relevant differences in mortality (due to e.g. their age) and risk-related traits (such as their behaviour and number of daily person-to-person interactions). Vaccination distribution strategies were evaluated for different vaccine effectiveness levels, population coverage and vaccination rate using data mainly from Spain. Findings: Our results show that, if children could also be included in the vaccination, a rollout by priority to groups with the highest number of daily person-to-person interactions can achieve large reductions in total fatalities. This is due to the importance of the avoided subsequent infections inflicted on the rest of the population by highly interactive individuals. If children are excluded from the vaccination, the differences between priority strategies become smaller and appear highly depending on rollout rate, coverage and the levels of self-protection and awareness exercised by the population. Interpretation: These results are in possible contradiction with several published plans for COVID-19 vaccination and highlight the importance of conducting an open comprehensive and thorough analysis of this problem leaving behind possible preconceptions.
COVID-19 has widely spread across the world, and much research is being conducted on the causative virus SARS-CoV-2. To help control the infection, we developed the Coronavirus GenBrowser (CGB) to monitor the pandemic. With CGB, 178,765 high quality SARS-CoV-2 genomic sequences were analyzed, and 121,522 mutations were identified. In total, 1,041 mutation cold spots were found, suggesting that these spots are key functional elements of SARS-CoV-2 and can be used for detection and vaccine development. CGB revealed 203 accelerated evolutions of SARS-CoV-2, but variants with accelerated evolution were not found to be highly contagious, suggesting that most of these evolutions are neutral. The B.1.1.7 (CGB75056.84017) lineage previously identified in the UK was not found to be significantly accelerated although its adaptive evolution was detected. Moreover, 2,297 strains with a significantly reduced evolutionary rate were identified, including three closely related variants widely spreading in Europe with no mutations in three months. By lineage tracing, a strain dated early March 2020 was determined to be the most recent common ancestor of nine strains collected from six different regions in three continents. This strain was also found to cause the outbreak in Xinfadi, Beijing, China in June 2020. CGB allows visualization and analysis of hundreds of thousands of SARS-CoV-2 genomic sequences. Distributed genome alignments and its effective analysis pipeline ensure timely update of the latest genomic data of SARS-CoV-2. CGB is an efficient platform for the general public to monitor the transmission and evolution of SARS-CoV-2.
Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19 - Condition: Covid19
Interventions: Biological: COVI-AMG; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms - Condition: Covid19
Interventions: Biological: COVI-AMG; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
An Effectiveness Study of the Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine - Condition: Covid19
Intervention: Biological: Adsorbed COVID-19 (Inactivated) Vaccine
Sponsor: Butantan Institute
Enrolling by invitation
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 - Condition: Severe COVID-19
Interventions: Drug: VB-201 + Standard of care; Drug: Standard of care
Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience - Condition: Covid19
Intervention: Drug: Tocilizumab
Sponsor: FMH College of Medicine and Dentistry
Completed
Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection - Conditions: Covid19; SARS-CoV 2
Intervention: Other: Sampling by venipuncture
Sponsor: Centre Hospitalier Régional d’Orléans
Recruiting
COVID-19 Convalescent Plasma Therapy - Conditions: SARS-CoV-2 Infection; COVID-19 Infection
Intervention: Biological: Convalescent plasma
Sponsors: Angelica Samudio; Consejo Nacional de Ciencias y Tecnología, Paraguay; Ministerio de Salud Pública y Bienestar Social, Paraguay; Centro de información y recursos para el desarrollo, Paraguay
Completed
An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization - Condition: Covid19
Interventions: Drug: Ivermectin Tablets; Drug: Doxycycline Tablets; Drug: Placebo
Sponsor: Max Health, Subsero Health
Recruiting
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 - Conditions: Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19
Interventions: Drug: SNG001; Drug: Placebo
Sponsor: Synairgen Research Ltd.
Recruiting
A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19) - Condition: Coronavirus Disease 2019 (COVID-19)
Interventions: Drug: Placebo; Drug: Prothione™ (6g)
Sponsor: Prothione, LLC
Not yet recruiting
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients - Condition: Covid19
Intervention: Drug: Ivermectin
Sponsor: FMH College of Medicine and Dentistry
Completed
AGILE (Early Phase Platform Trial for COVID-19) - Condition: Covid19
Interventions: Drug: CST-2: EIDD-2801; Drug: CST-2: Placebo
Sponsors: University of Liverpool; University of Southampton; Liverpool School of Tropical Medicine; Lancaster University; Liverpool University Hospitals NHS Foundation Trust
Recruiting
Community Network-driven COVID-19 Testing of Vulnerable Populations in the Central US - Condition: Covid19
Intervention: Other: Social Network Strategy + COVID-19 messaging
Sponsor: University of Chicago
Not yet recruiting
Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19 - Condition: Covid19
Interventions: Drug: GX-I7; Drug: GX-I7 vehicle
Sponsor: Genexine, Inc.
Recruiting
Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection - Condition: COVID-19
Intervention: Drug: Cannabidiol
Sponsor: Rabin Medical Center
Recruiting
Amino acid sensing pathway: A major check point in the pathogenesis of obesity and COVID-19 - Obesity and obesogenic comorbidities have been associated with COVID-19 susceptibility and mortality. However, the mechanism of such correlations requires an in-depth understanding. Overnutrition/excess serum amino acid profile during obesity has been linked with inflammation and reprogramming of translational machinery through hyperactivation of amino acid sensor mammalian target of rapamycin (mTOR), which is exploited by SARS-CoV-2 for its replication. Conversely, we have shown that the…
Hsp90 inhibition protects the brain microvascular endothelium against oxidative stress - The brain endothelium is an integral element of the blood-brain barrier (BBB). Dysfunction of this formation due to increased generation of reactive oxygen species (ROS) progresses the establishment of neurological disorders including stroke and traumatic brain injury. Heat shock protein 90 inhibitors are anti-inflammatory agents, and their activities are mediated, at least in part, by P53. This is a tumor suppressor protein which regulates the opposing activities of Rac1 and RhoA in the…
Overview on the Discovery and Development of Anti-Inflammatory Drugs: Should the Focus Be on Synthesis or Degradation of PGE(2)? - Inflammation is a protective response that develops against tissue injury and infection. Chronic inflammation, on the other hand, is the key player in the pathogenesis of many inflammatory disorders including cancer. The cytokine storm, an inflammatory response flaring out of control, is mostly responsible for the mortality in COVID-19 patients. Anti-inflammatory drugs inhibit cyclooxygenases (COX), which are involved in the biosynthesis of prostaglandins that promote inflammation. The…
Porcine Epidemic Diarrhea Virus Infection Induces Caspase-8 mediated G3BP1 Cleavage and Subverts Stress Granules to Promote Viral Replication - Porcine Epidemic Diarrhea Virus (PEDV) is an α-coronavirus causing severe diarrhea and high mortality rates in suckling piglets and posing significant economic impact. PEDV replication is completed and results in a large amount of RNA in the cytoplasm. Stress granules (SGs) are dynamic cytosolic RNA granules formed under various stress conditions including viral infections. Several previous studies suggested that SGs were involved in the antiviral activity of host cells to limit viral…
SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO - Coronavirus disease 2019 (COVID-19) is a current global health threat caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging evidence indicates that SARS-CoV-2 elicits a dysregulated immune response and a delayed interferon (IFN) expression in patients, which contribute largely to the viral pathogenesis and development of COVID-19. However, underlying mechanisms remain to be elucidated. Here, we report the activation and repression of the innate…
Photosynthetically Controlled Spirulina, but Not Solar Spirulina, Inhibits TNF-alpha Secretion: Potential Implications for COVID-19-Related Cytokine Storm Therapy - An array of infections, including the novel coronavirus (SARS-CoV-2), trigger macrophage activation syndrome (MAS) and subsequently hypercytokinemia, commonly referred to as a cytokine storm (CS). It is postulated that CS is mainly responsible for critical COVID-19 cases, including acute respiratory distress syndrome (ARDS). Recognizing the therapeutic potential of Spirulina blue-green algae (Arthrospira platensis), in this in vitro stimulation study, LPS-activated macrophages and monocytes were…
Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2 - The recent outbreak of the SARS-CoV-2 infection has affected the lives and economy of more than 200 countries. The unavailability of virus-specific drugs has created an opportunity to identify potential therapeutic agents that can control the rapid transmission of this pandemic. Here, the mechanisms of the inhibition of the RNA-dependent RNA polymerase (RdRp), responsible for the replication of the virus in host cells, are examined by different ligands, such as Remdesivir (RDV), Remdesivir…
Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 Infection - Global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still ongoing. Before an effective vaccine is available, the development of potential treatments for resultant coronavirus disease 2019 (COVID-19) is crucial. One of disease hallmarks is hyper-inflammatory responses, which usually leads to a severe lung disease. Patients with COVID-19 also frequently suffered from neurological symptoms such as acute diffuse encephalomyelitis, brain injury and psychiatric…
The basis of a more contagious 501Y.V1 variant of SARS-COV-2 - Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is causing a world-wide pandemic. A variant of SARS-COV-2 (20I/501Y.V1) recently discovered in the United Kingdom has a single mutation from N501 to Y501 within the receptor binding domain (Y501-RBD), of the Spike protein of the virus. This variant is much more contagious than the original version (N501-RBD). We found that this mutated version of RBD binds to human Angiotensin Converting Enzyme 2 (ACE2) a ~10 times more tightly…
Identification of the SHREK family of proteins as broad-spectrum host antiviral factors - Mucins and mucin-like molecules are highly glycosylated, high-molecular-weight cell surface proteins that possess a semi-rigid and highly extended extracellular domain. P-selectin glycoprotein ligand-1 (PSGL-1), a mucin-like glycoprotein, has recently been found to restrict HIV-1 infectivity through virion incorporation that sterically hinders virus particle attachment to target cells. Here, we report the identification of a family of antiviral cellular proteins, named the Surface-Hinged,…
Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection - The newly emerged SARS-CoV-2 caused a global pandemic with astonishing mortality and morbidity. The mechanisms underpinning its highly infectious nature remain poorly understood. We report here that SARS-CoV-2 exploits cellular CTP synthetase 1 (CTPS1) to promote CTP synthesis and suppress interferon (IFN) induction. Screening a SARS-CoV-2 expression library identified ORF7b and ORF8 that suppressed IFN induction via inducing the deamidation of interferon regulatory factor 3 (IRF3). Deamidated…
Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells - BACKGROUND: The SARS-CoV-2 virus has caused the death of over 2 million people worldwide during the COVID-19 pandemic. Whilst effective vaccines have been developed and vaccination schedules are being rolled out, the identification of safe and inexpensive drugs to slow the replication of SARS-CoV-2 could help thousands of people worldwide whilst awaiting vaccination.
Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2 - The type II transmembrane serine protease TMPRSS2 facilitates the entry of coronaviruses, such as SARS-CoV-2, into host cells by cleaving the S(1)/S(2) interface of the viral spike protein. Based on structural data derived from X-ray crystallographic data of related trypsin-like proteases, a homology model of TMPRSS2 is described and validated using the broad spectrum COVID-19 drug candidate camostat as a probe. Both active site recognition and catalytic function are examined using quantum…
Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2 - SARS-CoV-2 Nsp15 is a uridine-specific endoribonuclease with C-terminal catalytic domain belonging to the EndoU family that is highly conserved in coronaviruses. As endoribonuclease activity seems to be responsible for the interference with the innate immune response, Nsp15 emerges as an attractive target for therapeutic intervention. Here we report the first structures with bound nucleotides and show how the enzyme specifically recognizes uridine moiety. In addition to a uridine site we present…
The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to Type I interferon and IFITM2 - The cellular entry of severe acute respiratory syndrome-associated coronaviruses types 1 and 2 (SARS-CoV-1 and -2) requires sequential protease processing of the viral spike glycoprotein. The presence of a polybasic cleavage site in SARS-CoV-2 spike at the S1/S2 boundary has been suggested to be a factor in the increased transmissibility of SARS-CoV-2 compared to SARS-CoV-1 by facilitating maturation of the spike precursor by furin-like proteases in the producer cells rather than endosomal…
SARS-CoV-2 antibodies - - link
SARS-CoV-2 antibodies - - link
A PHARMACEUTICAL COMPOSITION OF NITAZOXANIDE AND MEFLOQUINE AND METHOD THEREOF - A pharmaceutical composition for treating Covid-19 virus comprising a therapeutically effective amount of a nitazoxanide or its pharmaceutically acceptable salts thereof and an mefloquine or its pharmaceutically acceptable salts thereof is disclosed. The pharmaceutical composition comprises the nitazoxanide in the ratio of 0.05% to 66% w/v and the mefloquine in the ratio of 0.05% to 90% w/v. The composition is found to be effective for the treatment of COVID -19 (SARS-CoV2). The pharmaceutical composition of nitazoxanide and mefloquine has been found to be effective and is unexpectedly well tolerated with a low rate of side-effects, and equally high cure-rates than in comparable treatments. - link
TREATMENT OF COVID-19 WITH REBAMIPIDE - - link
METHOD AND APPARATUS FOR ACQUIRING POWER CONSUMPTION IMPACT BASED ON IMPACT OF COVID-19 EPIDEMIC - - link
一种新冠肺炎CT检测识别定位系统及计算设备 - 本发明涉及图像处理领域,公开了一种新冠肺炎CT检测识别定位系统及计算设备,包括图像采集单元、模块建立单元、新冠肺炎病灶识别单元和新冠肺炎病灶定位单元;图像采集单元采集待识别检测新冠肺炎的CT图像、新冠肺炎CT影像病灶分割训练数据集和新冠CT图像识别训练集;模块建立单元建立U_Net卷积神经网络模型、加入注意力机制的InceptionV3网络和目标检测模型;新冠肺炎病灶识别单元对已分割出病灶的轮廓特征图像进行识别;新冠肺炎病灶定位单元确定病灶在人体肺部的位置。本发明利用U_Net卷积神经网络模型对新冠病灶检测分割,并通过加入注意力机制的网络进行新冠肺炎识别,通过目标检测模型定位病灶在肺部的位置,识别准确率高,计算速度快。 - link
一种基于磁微粒化学发光的新型冠状病毒抗体检测试剂盒 - 本发明提供一种基于磁微粒化学发光的新型冠状病毒抗体检测试剂盒。所述检测试剂盒包括:链霉亲和素磁微粒、生物素标记的新型冠状病毒抗原、吖啶磺酰胺标记的二抗、样本稀释液和质控品;所述生物素标记的新型冠状病毒抗原包括重组核衣壳蛋白和重组棘突蛋白S1。将待检样本、生物素标记抗原与链霉亲和素磁微粒混合,孵育和洗涤,再加入吖啶磺酰胺标记的抗体,形成磁微粒‑链霉亲和素‑生物素‑抗原‑新型冠状病毒抗体‑二抗复合物,进而检测发光强度实现对待测样品的定性。 - link
A PHARMACEUTICAL COMPOSITION OF ARTESUNATE AND MEFLOQUINE AND METHOD THEREOF - A pharmaceutical composition for treating Covid-19 virus comprising a therapeutically effective amount of an artesunate or its pharmaceutically acceptable salts thereof and a mefloquine or its pharmaceutically acceptable salts thereof is disclosed. The pharmaceutical composition comprises the artesunate in the ratio of 0.25% to 66% w/v and mefloquine in the ratio of 0.25% to 90% w/v. The composition is found to be effective for the treatment of COVID -19 (SARS-CoV2). The pharmaceutical composition of Artesunate and Mefloquine has been found to be effective and is unexpectedly well tolerated with a low rate of side-effects, and equally high cure-rates than in comparable treatments. The present invention also discloses a method to preparing the pharmaceutical composition comprising of Artesunate and Mefloquine. - link
Zahnbürstenaufsatz für eine elektrische Zahnbürste (20) umfassend einen Koppelabschnitt (2), über den der Zahnbürstenaufsatz (1) mit einer elektrischen Versorgungseinheit (10) der elektrischen Zahnbürste (20) verbindbar ist und einen Bürstenabschnitt (3), der zur Reinigung der Zähne ausgebildete Reinigungsmittel (3.1) aufweist, dadurch gekennzeichnet, dass an dem Zahnbürstenaufsatz (1) eine Sensoreinheit (4) vorgesehen ist, die dazu ausgebildet ist, selektiv das Vorhandensein eines Virus oder eines Antigen im Speichel eines Nutzers des Zahnbürstenaufsatzes (1) durch Messen zumindest eines virusspezifischen Parameters zu bestimmen.
一种医用可佩戴式防护口鼻的微型气幕系统 - 本发明公开了一种医用可佩戴式防护口鼻的微型气幕系统,包括框柱,框柱一侧开凿有气幕送风口和呼吸用送风口,气幕送风口和呼吸用送风口内分别连接有软管一和软管二,框柱内开凿有水平条缝和垂直条缝,水平条缝与垂直条缝均与气幕送风口相连通,框柱靠近水平条缝的一侧贯穿开凿有出风口,出风口内设有滤网,出风口贯穿框柱的一端连接有高效过滤器,滤网与高效过滤器之间连接有吸气泵,框柱靠近出风口的一侧连接有电池和开关。本发明通过提出一种在口腔处应用洁净空气幕阻挡气溶胶传播的可佩戴装置,可以在口腔类相关诊疗过程,保护医生和周围人的健康,避免引起可能引发的呼吸道疾病交叉感染。 - link